A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections

F. Matsumoto; M. Inoue; I. Sakurai; Y. Ishida; T. Osonoi; H. Itoh; H. Inoue; K. Yamauchi; K. Shirato; I. Ohno; M. Sakamoto; T. Nukiwa; A. Watanabe; Y. Nakai; S. Shoji; Y. Honda; K. Niizuma; Y. Anzai; Y. Anazawa; N. Aso; H. Takahashi; S. Nakayama; K. Yanase; M. Nakamura; T. Toyoda; K. Dote; A. Tsunami; K. Wada; F. Iwata; Y. Shimazu; K. Fujimori; N. Aoki; Y. Ishizuka; O. Sekine; Y. Suzuki; K. Kaneko; K. Shimada; K. Nakano; Y. Sano; C. Ogawa; Y. Toh; O. Sakai; T. Hosoya; K. Shiba; M. Yoshida; K. Yoshikawa; K. Kasai; T. Kimura; K. Hirano; M. Fukakusa; K. Watanabe; H. Isonuma; K. Nakata; H. Narui; T. Nakatani; S. Honma; E. Tsuboi; K. Kishi; M. Kawabata; K. Kudo; A. Kawana; H. Miyashita; Y. Ono; H. Nishiya; H. Kobayashi; S. Sakayori; H. Miura; S. Takayasu; S. Irimajiri; Y. Matsuoka; M. Obana; T. Okubo; H. Ikeda; M. Nishikawa; K. Tani; H. Hasegawa; H. Sakamoto; H. Numata; M. Hashimoto; M. Matsumura; M. Satoh; M. Nakamura; Y. Hirai; T. Nakamura; T. Iwabuchi; S. Odagiri; K. Suzuki; Y. Watanuki; H. Takahashi; K. Takahashi; Y. Yoshiike; T. Ogura; M. Toda; H. Nishiyama; A. Shoji; Y. Ishimaru; T. Yoshimi; H. Nakanura; A. Sato

A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections

F. Matsumoto, M. Inoue, I. Sakurai, Y. Ishida, T. Osonoi, H. Itoh, H. Inoue, K. Yamauchi, K. Shirato, I. Ohno, M. Sakamoto, T. Nukiwa, A. Watanabe, Y. Nakai, S. Shoji, Y. Honda, K. Niizuma, Y. Anzai, Y. Anazawa, N. AsoH. Takahashi, S. Nakayama, K. Yanase, M. Nakamura, T. Toyoda, K. Dote, A. Tsunami, K. Wada, F. Iwata, Y. Shimazu, K. Fujimori, N. Aoki, Y. Ishizuka, O. Sekine, Y. Suzuki, K. Kaneko, K. Shimada, K. Nakano, Y. Sano, C. Ogawa, Y. Toh, O. Sakai, T. Hosoya, K. Shiba, M. Yoshida, K. Yoshikawa, K. Kasai, T. Kimura, K. Hirano, M. Fukakusa, K. Watanabe, H. Isonuma, K. Nakata, H. Narui, T. Nakatani, S. Honma, E. Tsuboi, K. Kishi, M. Kawabata, K. Kudo, A. Kawana, H. Miyashita, Y. Ono, H. Nishiya, H. Kobayashi, S. Sakayori, H. Miura, S. Takayasu, S. Irimajiri, Y. Matsuoka, M. Obana, T. Okubo, H. Ikeda, M. Nishikawa, K. Tani, H. Hasegawa, H. Sakamoto, H. Numata, M. Hashimoto, M. Matsumura, M. Satoh, M. Nakamura, Y. Hirai, T. Nakamura, T. Iwabuchi, S. Odagiri, K. Suzuki, Y. Watanuki, H. Takahashi, K. Takahashi, Y. Yoshiike, T. Ogura, M. Toda, H. Nishiyama, A. Shoji, Y. Ishimaru, T. Yoshimi, H. Nakanura, A. Sato

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

The clinical efficacy, safety and usefulness of biapenem (BIPM), a carbapenem antibiotic for injection, were evaluated in lower respiratory infections in a comparative study with imipenem/cilasstatin (IPM/CS). BIPM and IPM/CS were administered by intravenous drip infusion at a dose of 300 mg twice daily and 500 mg/500 mg twice daily. The duration of treatment was within 14 days. The following results were obtained. 1. A total of 214 cases were enrolled in this study, consisting of 103 in the BIPM group and 111 in the IPM/CS group. The clinical efficacy was evaluated in 88 of the BIPM group and 93 of the IPM/CS group, the overall safety was evaluated in 101 of the BIPM group and 110 of the IPM/CS group, and the usefulness was evaluated in 89 of the BIPM group and 101 of the IPM/CS group. 2. The clinical efficacy rates were 93.2% (82/88) in the BIPM group and 91.4% (85/93) in the IPM/CS group. The 90% confidence interval of the difference between the two groups was -5.8% to 9.4%, and the clinical non inferiority of BIPM to IPM/CS was demonstrated. For the evaluation of early onset after 3 days of treatment, the early clinical efficacy rates were 84.1% (74/88) in the BIPM group and 76.3% (71/93) in the IPM/CS group, with no significant difference between the two groups. 3. The bacteriological eradication rates were 89.1% (41/46) in the BIPM group and 97.5% (39/40) in the IPM/CS group, with no significant difference between the two groups. 4. Side effects were observed at a rate of 1.9% (2/103)in the BIPM group and 6.3% (7/111) in the IPM/CS group, with no significant difference between the two groups. Abnormal laboratory findings were observed at a rate of 26.2% (27/103) in the BIPM group and 43.2% (48/111) in the IPM/CS group, with significant difference between the two groups. The safety rates were 98.0% (99/101) in the BIPM group and 96.4% (106/110) in the IPM/CS group, with no significant difference between the two groups. 5. The usefulness rates were 88.8% (79/89) in the BIPM group and 81.2% (82/101) in the IPM/CS group, with no significant difference between the two groups. These results demonstrate that BIPM is a useful drug for the treatment of lower respiratory tract infections.

Original language	English
Pages (from-to)	45-67
Number of pages	23
Journal	Japanese Journal of Chemotherapy
Volume	48
Issue number	1
Publication status	Published - 2000
Externally published	Yes

Keywords

Biapenem
Imipenem/cilastatin

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Cite this

Matsumoto, F., Inoue, M., Sakurai, I., Ishida, Y., Osonoi, T., Itoh, H., Inoue, H., Yamauchi, K., Shirato, K., Ohno, I., Sakamoto, M., Nukiwa, T., Watanabe, A., Nakai, Y., Shoji, S., Honda, Y., Niizuma, K., Anzai, Y., Anazawa, Y., ... Sato, A. (2000). A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections. Japanese Journal of Chemotherapy, 48(1), 45-67.

Matsumoto, F, Inoue, M, Sakurai, I, Ishida, Y, Osonoi, T, Itoh, H, Inoue, H, Yamauchi, K, Shirato, K, Ohno, I, Sakamoto, M, Nukiwa, T, Watanabe, A, Nakai, Y, Shoji, S, Honda, Y, Niizuma, K, Anzai, Y, Anazawa, Y, Aso, N, Takahashi, H, Nakayama, S, Yanase, K, Nakamura, M, Toyoda, T, Dote, K, Tsunami, A, Wada, K, Iwata, F, Shimazu, Y, Fujimori, K, Aoki, N, Ishizuka, Y, Sekine, O, Suzuki, Y, Kaneko, K, Shimada, K, Nakano, K, Sano, Y, Ogawa, C, Toh, Y, Sakai, O, Hosoya, T, Shiba, K, Yoshida, M, Yoshikawa, K, Kasai, K, Kimura, T, Hirano, K, Fukakusa, M, Watanabe, K, Isonuma, H, Nakata, K, Narui, H, Nakatani, T, Honma, S, Tsuboi, E, Kishi, K, Kawabata, M, Kudo, K, Kawana, A, Miyashita, H, Ono, Y, Nishiya, H, Kobayashi, H, Sakayori, S, Miura, H, Takayasu, S, Irimajiri, S, Matsuoka, Y, Obana, M, Okubo, T, Ikeda, H, Nishikawa, M, Tani, K, Hasegawa, H, Sakamoto, H, Numata, H, Hashimoto, M, Matsumura, M, Satoh, M, Nakamura, M, Hirai, Y, Nakamura, T, Iwabuchi, T, Odagiri, S, Suzuki, K, Watanuki, Y, Takahashi, H, Takahashi, K, Yoshiike, Y, Ogura, T, Toda, M, Nishiyama, H, Shoji, A, Ishimaru, Y, Yoshimi, T, Nakanura, H & Sato, A 2000, 'A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections', Japanese Journal of Chemotherapy, vol. 48, no. 1, pp. 45-67.

@article{ceb05b36b8be43dfb7c4be189877131c,

title = "A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections",

abstract = "The clinical efficacy, safety and usefulness of biapenem (BIPM), a carbapenem antibiotic for injection, were evaluated in lower respiratory infections in a comparative study with imipenem/cilasstatin (IPM/CS). BIPM and IPM/CS were administered by intravenous drip infusion at a dose of 300 mg twice daily and 500 mg/500 mg twice daily. The duration of treatment was within 14 days. The following results were obtained. 1. A total of 214 cases were enrolled in this study, consisting of 103 in the BIPM group and 111 in the IPM/CS group. The clinical efficacy was evaluated in 88 of the BIPM group and 93 of the IPM/CS group, the overall safety was evaluated in 101 of the BIPM group and 110 of the IPM/CS group, and the usefulness was evaluated in 89 of the BIPM group and 101 of the IPM/CS group. 2. The clinical efficacy rates were 93.2% (82/88) in the BIPM group and 91.4% (85/93) in the IPM/CS group. The 90% confidence interval of the difference between the two groups was -5.8% to 9.4%, and the clinical non inferiority of BIPM to IPM/CS was demonstrated. For the evaluation of early onset after 3 days of treatment, the early clinical efficacy rates were 84.1% (74/88) in the BIPM group and 76.3% (71/93) in the IPM/CS group, with no significant difference between the two groups. 3. The bacteriological eradication rates were 89.1% (41/46) in the BIPM group and 97.5% (39/40) in the IPM/CS group, with no significant difference between the two groups. 4. Side effects were observed at a rate of 1.9% (2/103)in the BIPM group and 6.3% (7/111) in the IPM/CS group, with no significant difference between the two groups. Abnormal laboratory findings were observed at a rate of 26.2% (27/103) in the BIPM group and 43.2% (48/111) in the IPM/CS group, with significant difference between the two groups. The safety rates were 98.0% (99/101) in the BIPM group and 96.4% (106/110) in the IPM/CS group, with no significant difference between the two groups. 5. The usefulness rates were 88.8% (79/89) in the BIPM group and 81.2% (82/101) in the IPM/CS group, with no significant difference between the two groups. These results demonstrate that BIPM is a useful drug for the treatment of lower respiratory tract infections.",

keywords = "Biapenem, Imipenem/cilastatin",

author = "F. Matsumoto and M. Inoue and I. Sakurai and Y. Ishida and T. Osonoi and H. Itoh and H. Inoue and K. Yamauchi and K. Shirato and I. Ohno and M. Sakamoto and T. Nukiwa and A. Watanabe and Y. Nakai and S. Shoji and Y. Honda and K. Niizuma and Y. Anzai and Y. Anazawa and N. Aso and H. Takahashi and S. Nakayama and K. Yanase and M. Nakamura and T. Toyoda and K. Dote and A. Tsunami and K. Wada and F. Iwata and Y. Shimazu and K. Fujimori and N. Aoki and Y. Ishizuka and O. Sekine and Y. Suzuki and K. Kaneko and K. Shimada and K. Nakano and Y. Sano and C. Ogawa and Y. Toh and O. Sakai and T. Hosoya and K. Shiba and M. Yoshida and K. Yoshikawa and K. Kasai and T. Kimura and K. Hirano and M. Fukakusa and K. Watanabe and H. Isonuma and K. Nakata and H. Narui and T. Nakatani and S. Honma and E. Tsuboi and K. Kishi and M. Kawabata and K. Kudo and A. Kawana and H. Miyashita and Y. Ono and H. Nishiya and H. Kobayashi and S. Sakayori and H. Miura and S. Takayasu and S. Irimajiri and Y. Matsuoka and M. Obana and T. Okubo and H. Ikeda and M. Nishikawa and K. Tani and H. Hasegawa and H. Sakamoto and H. Numata and M. Hashimoto and M. Matsumura and M. Satoh and M. Nakamura and Y. Hirai and T. Nakamura and T. Iwabuchi and S. Odagiri and K. Suzuki and Y. Watanuki and H. Takahashi and K. Takahashi and Y. Yoshiike and T. Ogura and M. Toda and H. Nishiyama and A. Shoji and Y. Ishimaru and T. Yoshimi and H. Nakanura and A. Sato",

year = "2000",

language = "English",

volume = "48",

pages = "45--67",

journal = "Japanese Journal of Chemotherapy",

issn = "1340-7007",

publisher = "Japan Society of Chemotherapy",

number = "1",

}

TY - JOUR

T1 - A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections

AU - Matsumoto, F.

AU - Inoue, M.

AU - Sakurai, I.

AU - Ishida, Y.

AU - Osonoi, T.

AU - Itoh, H.

AU - Inoue, H.

AU - Yamauchi, K.

AU - Shirato, K.

AU - Ohno, I.

AU - Sakamoto, M.

AU - Nukiwa, T.

AU - Watanabe, A.

AU - Nakai, Y.

AU - Shoji, S.

AU - Honda, Y.

AU - Niizuma, K.

AU - Anzai, Y.

AU - Anazawa, Y.

AU - Aso, N.

AU - Takahashi, H.

AU - Nakayama, S.

AU - Yanase, K.

AU - Nakamura, M.

AU - Toyoda, T.

AU - Dote, K.

AU - Tsunami, A.

AU - Wada, K.

AU - Iwata, F.

AU - Shimazu, Y.

AU - Fujimori, K.

AU - Aoki, N.

AU - Ishizuka, Y.

AU - Sekine, O.

AU - Suzuki, Y.

AU - Kaneko, K.

AU - Shimada, K.

AU - Nakano, K.

AU - Sano, Y.

AU - Ogawa, C.

AU - Toh, Y.

AU - Sakai, O.

AU - Hosoya, T.

AU - Shiba, K.

AU - Yoshida, M.

AU - Yoshikawa, K.

AU - Kasai, K.

AU - Kimura, T.

AU - Hirano, K.

AU - Fukakusa, M.

AU - Watanabe, K.

AU - Isonuma, H.

AU - Nakata, K.

AU - Narui, H.

AU - Nakatani, T.

AU - Honma, S.

AU - Tsuboi, E.

AU - Kishi, K.

AU - Kawabata, M.

AU - Kudo, K.

AU - Kawana, A.

AU - Miyashita, H.

AU - Ono, Y.

AU - Nishiya, H.

AU - Kobayashi, H.

AU - Sakayori, S.

AU - Miura, H.

AU - Takayasu, S.

AU - Irimajiri, S.

AU - Matsuoka, Y.

AU - Obana, M.

AU - Okubo, T.

AU - Ikeda, H.

AU - Nishikawa, M.

AU - Tani, K.

AU - Hasegawa, H.

AU - Sakamoto, H.

AU - Numata, H.

AU - Hashimoto, M.

AU - Matsumura, M.

AU - Satoh, M.

AU - Nakamura, M.

AU - Hirai, Y.

AU - Nakamura, T.

AU - Iwabuchi, T.

AU - Odagiri, S.

AU - Suzuki, K.

AU - Watanuki, Y.

AU - Takahashi, H.

AU - Takahashi, K.

AU - Yoshiike, Y.

AU - Ogura, T.

AU - Toda, M.

AU - Nishiyama, H.

AU - Shoji, A.

AU - Ishimaru, Y.

AU - Yoshimi, T.

AU - Nakanura, H.

AU - Sato, A.

PY - 2000

Y1 - 2000

N2 - The clinical efficacy, safety and usefulness of biapenem (BIPM), a carbapenem antibiotic for injection, were evaluated in lower respiratory infections in a comparative study with imipenem/cilasstatin (IPM/CS). BIPM and IPM/CS were administered by intravenous drip infusion at a dose of 300 mg twice daily and 500 mg/500 mg twice daily. The duration of treatment was within 14 days. The following results were obtained. 1. A total of 214 cases were enrolled in this study, consisting of 103 in the BIPM group and 111 in the IPM/CS group. The clinical efficacy was evaluated in 88 of the BIPM group and 93 of the IPM/CS group, the overall safety was evaluated in 101 of the BIPM group and 110 of the IPM/CS group, and the usefulness was evaluated in 89 of the BIPM group and 101 of the IPM/CS group. 2. The clinical efficacy rates were 93.2% (82/88) in the BIPM group and 91.4% (85/93) in the IPM/CS group. The 90% confidence interval of the difference between the two groups was -5.8% to 9.4%, and the clinical non inferiority of BIPM to IPM/CS was demonstrated. For the evaluation of early onset after 3 days of treatment, the early clinical efficacy rates were 84.1% (74/88) in the BIPM group and 76.3% (71/93) in the IPM/CS group, with no significant difference between the two groups. 3. The bacteriological eradication rates were 89.1% (41/46) in the BIPM group and 97.5% (39/40) in the IPM/CS group, with no significant difference between the two groups. 4. Side effects were observed at a rate of 1.9% (2/103)in the BIPM group and 6.3% (7/111) in the IPM/CS group, with no significant difference between the two groups. Abnormal laboratory findings were observed at a rate of 26.2% (27/103) in the BIPM group and 43.2% (48/111) in the IPM/CS group, with significant difference between the two groups. The safety rates were 98.0% (99/101) in the BIPM group and 96.4% (106/110) in the IPM/CS group, with no significant difference between the two groups. 5. The usefulness rates were 88.8% (79/89) in the BIPM group and 81.2% (82/101) in the IPM/CS group, with no significant difference between the two groups. These results demonstrate that BIPM is a useful drug for the treatment of lower respiratory tract infections.

AB - The clinical efficacy, safety and usefulness of biapenem (BIPM), a carbapenem antibiotic for injection, were evaluated in lower respiratory infections in a comparative study with imipenem/cilasstatin (IPM/CS). BIPM and IPM/CS were administered by intravenous drip infusion at a dose of 300 mg twice daily and 500 mg/500 mg twice daily. The duration of treatment was within 14 days. The following results were obtained. 1. A total of 214 cases were enrolled in this study, consisting of 103 in the BIPM group and 111 in the IPM/CS group. The clinical efficacy was evaluated in 88 of the BIPM group and 93 of the IPM/CS group, the overall safety was evaluated in 101 of the BIPM group and 110 of the IPM/CS group, and the usefulness was evaluated in 89 of the BIPM group and 101 of the IPM/CS group. 2. The clinical efficacy rates were 93.2% (82/88) in the BIPM group and 91.4% (85/93) in the IPM/CS group. The 90% confidence interval of the difference between the two groups was -5.8% to 9.4%, and the clinical non inferiority of BIPM to IPM/CS was demonstrated. For the evaluation of early onset after 3 days of treatment, the early clinical efficacy rates were 84.1% (74/88) in the BIPM group and 76.3% (71/93) in the IPM/CS group, with no significant difference between the two groups. 3. The bacteriological eradication rates were 89.1% (41/46) in the BIPM group and 97.5% (39/40) in the IPM/CS group, with no significant difference between the two groups. 4. Side effects were observed at a rate of 1.9% (2/103)in the BIPM group and 6.3% (7/111) in the IPM/CS group, with no significant difference between the two groups. Abnormal laboratory findings were observed at a rate of 26.2% (27/103) in the BIPM group and 43.2% (48/111) in the IPM/CS group, with significant difference between the two groups. The safety rates were 98.0% (99/101) in the BIPM group and 96.4% (106/110) in the IPM/CS group, with no significant difference between the two groups. 5. The usefulness rates were 88.8% (79/89) in the BIPM group and 81.2% (82/101) in the IPM/CS group, with no significant difference between the two groups. These results demonstrate that BIPM is a useful drug for the treatment of lower respiratory tract infections.

KW - Biapenem

KW - Imipenem/cilastatin

UR - http://www.scopus.com/inward/record.url?scp=0033972977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033972977&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033972977

SN - 1340-7007

VL - 48

SP - 45

EP - 67

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

IS - 1

ER -

A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this